Travere Therapeutics, Inc. (TVTX): Price and Financial Metrics
TVTX Price/Volume Stats
| Current price | $8.40 | 52-week high | $26.55 |
| Prev. close | $8.42 | 52-week low | $7.00 |
| Day low | $8.25 | Volume | 97,048 |
| Day high | $8.44 | Avg. volume | 1,426,051 |
| 50-day MA | $13.47 | Dividend yield | N/A |
| 200-day MA | $17.86 | Market Cap | 630.09M |
TVTX Stock Price Chart Interactive Chart >
TVTX POWR Grades
- Value is the dimension where TVTX ranks best; there it ranks ahead of 70.07% of US stocks.
- The strongest trend for TVTX is in Quality, which has been heading down over the past 177 days.
- TVTX ranks lowest in Sentiment; there it ranks in the 3rd percentile.
TVTX Stock Summary
- TVTX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 82.95% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, TRAVERE THERAPEUTICS INC is reporting a growth rate of 37.67%; that's higher than 76.61% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TVTX comes in at -38.42% -- higher than that of just 12.92% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to TRAVERE THERAPEUTICS INC, a group of peers worth examining would be FCEL, KPTI, WATT, CASA, and FKWL.
- TVTX's SEC filings can be seen here. And to visit TRAVERE THERAPEUTICS INC's official web site, go to www.retrophin.com.
TVTX Valuation Summary
- In comparison to the median Healthcare stock, TVTX's EV/EBIT ratio is 126.72% lower, now standing at -3.1.
- TVTX's price/earnings ratio has moved down 0.6 over the prior 131 months.
Below are key valuation metrics over time for TVTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TVTX | 2023-09-22 | 2.6 | 5.1 | -1.9 | -3.1 |
| TVTX | 2023-09-21 | 2.5 | 4.9 | -1.9 | -3.1 |
| TVTX | 2023-09-20 | 4.3 | 8.3 | -3.1 | -4.4 |
| TVTX | 2023-09-19 | 4.4 | 8.5 | -3.2 | -4.5 |
| TVTX | 2023-09-18 | 4.4 | 8.6 | -3.3 | -4.5 |
| TVTX | 2023-09-15 | 4.5 | 8.8 | -3.3 | -4.6 |
TVTX Growth Metrics
- The 5 year revenue growth rate now stands at 32.8%.
- Its 3 year net income to common stockholders growth rate is now at -61.4%.
- The year over year net income to common stockholders growth rate now stands at 9.78%.
The table below shows TVTX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 212.018 | -186.291 | -278.482 |
| 2022-09-30 | 213.399 | -158.528 | -264.232 |
| 2022-06-30 | 228.12 | -86.94 | -230.215 |
| 2022-03-31 | 228.57 | -43.638 | -202.195 |
| 2021-12-31 | 227.49 | -14.792 | -180.091 |
| 2021-09-30 | 221.224 | -1.785 | -250.14 |
TVTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TVTX has a Quality Grade of C, ranking ahead of 60.91% of graded US stocks.
- TVTX's asset turnover comes in at 0.306 -- ranking 150th of 681 Pharmaceutical Products stocks.
- VTVT, FBRX, and NATR are the stocks whose asset turnover ratios are most correlated with TVTX.
The table below shows TVTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.306 | 0.969 | -0.399 |
| 2021-06-30 | 0.291 | 0.968 | -0.396 |
| 2021-03-31 | 0.289 | 0.968 | -0.412 |
| 2020-12-31 | 0.311 | 0.969 | -0.361 |
| 2020-09-30 | 0.304 | 0.970 | -0.166 |
| 2020-06-30 | 0.303 | 0.967 | -0.194 |
TVTX Price Target
For more insight on analysts targets of TVTX, see our TVTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.71 | Average Broker Recommendation | 1.25 (Strong Buy) |
Travere Therapeutics, Inc. (TVTX) Company Bio
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on identifying, developing, and delivering therapies to people living with rare disease. Travere Therapeutics serves customers worldwide.
Latest TVTX News From Around the Web
Below are the latest news stories about TRAVERE THERAPEUTICS INC that investors may wish to consider to help them evaluate TVTX as an investment opportunity.
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential effect of FILSPARI® (sparsentan) as a first-line therapy in patients with newly diagnosed IgA nephropathy (IgAN) in a late-breaking trial session at the 17th International Symposium on IgA Nephropathy (IIGANN2023) in Ryogoku, Tokyo, September 28-30, 2023. The Company will al |
Wayfair upgraded, Deere downgraded: Wall Street's top analyst callsToday's top research calls for upgrade, downgrade and initiate on stocks, as compiled by The Fly. |
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, IrbesartanFILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and eGFR chronic slope (1.1 mL/min/1.73m2 per year) [p=0.037]. Patients treated with FILSPARI over two years exhibited one of the slowest annual rates of kidney function decline seen in a clinical trial of IgAN patients (-2.7 to -2.9 mL/min/1.73m2 per year)eGFR chronic slope was statistically significant with respect to the confirmatory endpoint for the EU |
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 8,250 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Pl |
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere TherapeuticsFOSTER CITY, Calif. & SAN DIEGO, September 05, 2023--Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics |
TVTX Price Returns
| 1-mo | -43.51% |
| 3-mo | -45.35% |
| 6-mo | -59.87% |
| 1-year | -66.96% |
| 3-year | -56.17% |
| 5-year | N/A |
| YTD | -60.06% |
| 2022 | -32.25% |
| 2021 | 13.89% |
| 2020 | 91.94% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...